ARA-290

Nerve & pain In trials Human trials

Also called Cibinetide

An 11-amino-acid peptide modeled on one face of erythropoietin (EPO). It is built to trigger EPO's tissue-protective signaling without raising red blood cell counts. Most of the human work looks at small-fiber nerve damage and nerve pain in sarcoidosis and type 2 diabetes.

Why people take it

Nerve pain and neuropathySmall-fibre nerve repairInflammation in sarcoidosis

What studies report

Reduced neuropathic pain scores in sarcoidosis and type 2 diabetes trials
Regrowth of small nerve fibres in the cornea and skin
No rise in red blood cell count, unlike EPO itself

Worth knowing: Benefits came from phase 2 trials of a few hundred people; phase 3 confirmation is missing.

Status: Phase 2 trials completed. Not approved.

Route: Subcutaneous injection, from reconstituted lyophilised powder
Sequence: pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
Formula: C51H84N16O21
Molecular weight: 1257.3 g/mol
CAS: 1208243-50-8
Available as: 12 mg

View on PubChem →

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.